| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PHAR.1341 |
| P698 | PubMed publication ID | 23946152 |
| P2093 | author name string | Patrick F Smith | |
| Peter N Morcos | |||
| Barbara J Brennan | |||
| Mercidita T Navarro | |||
| Sebastian A Moreira | |||
| Nuria Bech | |||
| P2860 | cites work | Two New Rating Scales for Opiate Withdrawal | Q58291436 |
| Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) | Q27487391 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| Changes in plasma protein binding have little clinical relevance | Q34119864 | ||
| Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone | Q34348923 | ||
| Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone | Q34403471 | ||
| Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. | Q34543319 | ||
| Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir | Q34604652 | ||
| Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment | Q34893342 | ||
| Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. | Q35826204 | ||
| Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. | Q36053982 | ||
| Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir | Q36593838 | ||
| Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance | Q36641884 | ||
| Methadone maintenance treatment in opiate dependence: a review. | Q36887595 | ||
| Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients | Q37142229 | ||
| Induction effects of ritonavir: implications for drug interactions | Q37199533 | ||
| Methadone: a review of drug-drug and pathophysiological interactions | Q37950478 | ||
| New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives | Q38002789 | ||
| Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain | Q39538201 | ||
| Correlates of hepatitis C virus infections among injection drug users. | Q40453200 | ||
| Hepatitis C in methadone maintenance patients: prevalence and public policy implications | Q42646672 | ||
| Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects | Q42660244 | ||
| Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior | Q42985263 | ||
| Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients | Q43034694 | ||
| Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone | Q44346297 | ||
| Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study | Q44501592 | ||
| The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients | Q44540993 | ||
| Mechanism-based inactivation of CYP3A by HIV protease inhibitors | Q45137041 | ||
| Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. | Q45971154 | ||
| Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users | Q46154281 | ||
| Role of CYP2B6 in stereoselective human methadone metabolism | Q46739706 | ||
| HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. | Q48965078 | ||
| Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin. | Q50956303 | ||
| Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. | Q55240560 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ritonavir | Q422618 |
| Hepatitis C virus | Q708693 | ||
| pharmacokinetics | Q323936 | ||
| danoprevir | Q27271364 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 220-226 | |
| P577 | publication date | 2013-08-14 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy | |
| P478 | volume | 34 |
Search more.